PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…
September 18, 2025 16:30 ET | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals,…
In India's complex and expensive healthcare ecosystem, where sufferers still consume a significant portion of their income on pharmaceuticals, a…
September 11, 2025 09:00 ET | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows more than 50% reduction in photoreceptor loss caused…
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of…
AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…
August 01, 2025 16:55 ET | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE)…